Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and κB elements by cannabinol, a minimally CNS-active cannabinoid

Biochemical Pharmacology

Volumn 55, Issue 7, 1998, Pages 1013-1023

  Herring, Amy C ^a   Koh, Woo S ^a   Kaminski, Norbert E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

cAMP signaling cascade; Cannabinol; CREB; Immune suppression; NF B; Thymocytes

Indexed keywords

ADENYLATE CYCLASE; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; OKT 3; PHORBOL 13 ACETATE 12 MYRISTATE; TETRAHYDROCANNABINOL; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; GENE EXPRESSION; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; THYMOCYTE;

ACTIVATING TRANSCRIPTION FACTOR 2; ADENYLATE CYCLASE; ANIMALS; ANTIBODY FORMATION; CANNABINOL; CULTURE MEDIA; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FEMALE; FORSKOLIN; IMMUNOGLOBULIN M; LEUKOCYTES; MICE; MICE, INBRED STRAINS; NF-KAPPA B; SIGNAL TRANSDUCTION; SPLEEN; TRANSCRIPTION FACTORS;

EID: 0032055664     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00630-8     Document Type: Article

References (56)

1. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
2. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
3. i in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol. 29:1986;307-313.
4. Kaminski N.E., Koh W.S., Lee M., Yang K.H., Kessler F.K. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem Pharmacol. 48:1994;1899-1908.
5. Howlett A.C. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol. 27:1985;429-436.
6. 9-tetrahydrocannabinol in cultures of rat Sertoli cells. Toxicol Appl Pharmacol. 101:1989;124-134.
7. Rowley J.T., Rowley P.T. Tetrahydrocannabinol inhibits adenylate cyclase in human leukemia cells. Life Sci. 46:1989;217-222.
8. 9-tetrahydrocannabinol in mouse spleen cells A potential mechanism for cannabinoid-mediated immunosuppression . Life Sci. 51:1992;25-30.
9. Condie R.C., Herring A., Koh W.S., Lee M., Kaminski N.E. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and IL-2 expression in the murine T-cell line, EL4.IL-2. J Biol Chem. 271:1996;13175-13183.
10. 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-κB/Rel activation. Mol Pharmacol. 50:1996;334-341.
11. Felder C.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., Devane W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA. 90:1993;7656-7660.
12. Vogel Z., Barg J., Levy R., Saya D., Heldman E., Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem. 61:1993;352-355.
13. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2) Identification of cannabinoid receptor subtype selective ligands . J Pharmacol Exp Ther. 278:1996;989-999.
14. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 48:1995;443-450.
15. Schatz A.R., Lee M., Condie R.B., Pulaski J.T., Kaminski N.E. Cannabinoid receptors CB1 and CB2 A characterization of expression and adenylate cyclase modulation within the immune system . Toxicol Appl Pharmacol. 142:1997;278-287.
16. Kaminski N.E. Immunopharmacology and Immunotoxicology. 1994;Raven Press, New York.
17. Kaminski N.E. Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. Biochem Pharmacol. 52:1996;1133-1140.
18. Bouaboula M., Rinaldi M., Carayon P., Carillon C., Delpech B., Shire D., Le Fur G., Casellas P. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem. 214:1993;173-180.
19. Kaminski N.E., Abood M.E., Kessler F.K., Martin B.R., Schatz A.R. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells involved in cannabinoid-mediated immune modulation. Mol Pharmacol. 42:1992;736-742.
20. Lynn A.B., Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat Implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther. 268:1994;1612-1623.
21. Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., Le Fur G., Caput D., Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem. 270:1995;3726-3731.
22. 9-Tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function. Immunopharmacology. 26:1993;129-137.
23. Kaminski N.E., Holsapple M.P. Inhibition of macrophage accessory cell function in casein-treated B6C3F1 mice. J Immunol. 139:1987;1804-1810.
24. Francis D.A., Karras J.G., Ke X-Y, Sen R., Rothstein T.L. Induction of the transcription factors NF-κB, AP-1, and NF-AT during B cell stimulation through the CD40 receptor. Int Immunol. 7:1995;151-161.
25. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc. 50:1955;1096-1121.
26. Scherer L.J., Diamond R.A., Rothenberg E.V. Developmental regulation of cAMP signaling pathways in thymocyte development. Thymus. 23:1995;231-257.
27. Meinkoth J.L., Alberts A.S., Went W., Fantozzi D., Taylor S.S., Hagiwara M., Montminy M., Feramisco J.R. Signal transduction through the cAMP-dependent protein kinase. Mol Cell Biochem. 127/128:1993;179-186.
28. Hagiwara M., Brindle P., Harootunian A., Armstrong R., Rivier J., Vale W., Tsien R., Montminy M.R. Coupling of hormonal stimulation and transcription via the cyclic AMP-responsive factor CREB is rate limited by nuclear entry of protein kinase A. Mol Cell Biol. 13:1993;4852-4859.
29. Armstrong R., Wen W., Meinkoth J., Taylor S., Montminy M. A refractory phase in cyclic AMP-responsive transcription requires down regulation of protein kinase A. Mol Cell Biol. 15:1995;1826-1832.
30. Hagiwara M., Alberts A., Brindle P., Meinkoth J., Feramisco J., Deng T., Karin M., Shenolikar S., Montminy M. Transcriptional attenuation following cAMP induction requires PP-1-mediated dephosphorylation of CREB. Cell. 70:1992;105-113.
31. Shirakawa F., Mizel S. In vitro activation and nuclear translocation of NF-κB catalyzed by cyclic AMP-dependent protein kinase and protein kinase C. Mol Cell Biol. 9:1989;2424-2430.
32. Shirakawa F., Chedid M., Suttles J., Pollok B.A., Mizel S.B. Interleukin 1 and cyclic AMP induce κ immunoglobin light-chain expression via activation of an NF-κB-like DNA-binding protein. Mol Cell Biol. 9:1989;959-964.
33. Muroi M., Suzuk T. Role of protein kinase A in LPS-induced activation of NF-κB proteins of a mouse macrophage-like cell line, J774. Cell Signal. 5:1993;289-298.
34. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA. 92:1995;3376-3380.
35. Gonzalez G.A., Menzel P.J.L., Fischer W.H., Montminy M.R. Characterization of motifs which are critical for activity of the cyclic AMP-responsive transcription factor CREB. Mol Cell Biol. 11:1991;1306-1312.
36. Gonzalez G.A., Yamamoto K.K., Fischer W.H., Karr K., Menzel P., Briggs W.H. III, Vale W.W., Montminy M.R. A cluster of phosphorylation sites on the cAMP-regulated nuclear factor CREB predicted by its sequence. Nature. 337:1989;749-752.
37. Lee C.Q., Yun Y., Hoeffler J.P., Habener J.F. Cyclic-AMP-responsive transcriptional activation of CREB-327 involves interdependent phosphorylated subdomains. EMBO J. 9:1990;4455-4465.
38. Smith J.W., Steiner A.L., Newberry W.M., Parker C.W. Cyclic adenosine 3′,5′-monophosphate in human lymphocytes. Alteration after phytohemagglutinin. J Clin Invest. 50:1971;432-441.
39. Hadden J.W., Hadden E.M., Haddox M.K., Goldberg N.D. Guanosine 3′:5′-cyclic monophosphates A possible intracellular mediator of mitogenic influences in lymphocytes . Proc Natl Acad Sci USA. 69:1972;3024-3027.
40. Russell D.H. Type I cyclic AMP-dependent protein kinase as a positive effector of growth. Adv Cyclic Nucleotide Res. 9:1978;493-506.
41. Koh W.S., Yang K-H, Kaminski N.E. Cyclic AMP is an essential factor in immune responses. Biochem Biophys Res Commun. 206:1995;703-709.
42. Koh W.S., Lee M., Yang K-H, Kaminski N.E. Expression of functional glucagon receptors on lymphoid cells. Life Sci. 58:1996;741-751.
43. Feuerstein N., Huang D., Hinrichs S.H., Orten D.J., Aiyar N., Prystowsky M.B. Regulation of cAMP-responsive enhancer binding proteins during cell cycle progression in T lymphocytes stimulated by IL-2. J Immunol. 154:1995;68-79.
44. Feuerstein N., Firestein R., Aiyar N., He X., Murasko D., Cristofalo V. Late induction of CREB/ATF binding and a concomitant increase in cAMP levels in T and B lymphocytes stimulated via the antigen receptor. J Immunol. 156:1996;4582-4593.
45. Wollberg P., Soderqvist H., Nelson B. Mitogen activation of human peipheral T-lymphocytes induces the formation of new cyclic AMP response element-binding protein nuclear complexes. J Biol Chem. 269:1994;19719-19724.
46. Brindle P., Nakajima T., Montminy M. Multiple protein kinase A-regulated events are required for transcriptional induction by cAMP. Proc Natl Acad Sci USA. 92:1995;10521-10525.
47. Hsueh Y-P, Liang H-E, Ng S-Y, Lai M-Z. CD28-costimulation activates cyclic AMP-responsive element-binding protein in T lymphocytes. J Immunol. 158:1997;85-93.
48. 9-THC). A putative mechanism of cannabinoid-induced immune modulation. Biochem Pharmacol. 53:1997;1477-1484.
49. Barton K., Muthusamy N., Chanyangam M., Fischer C., Clendenin C., Leiden J.M. Defective thymocyte proliferation and IL-2 production in transgenic mice expressing a dominant-negative form of CREB. Nature. 379:1996;81-85.
50. Koide M., Kawahara Y., Nakayama I., Tsuda T., Yokoyama M. Cyclic AMP-elevating agents induce an inducible type of nitric oxide synthase in cultured vascular smooth muscle cells. Synergism with the induction elicited by inflammatory cytokines. J Biol Chem. 268:1993;24959-24966.
51. Alonso A., Carvalho J., Alonso-Torre S., Nunex L., Bosca L., Crespo M. Nitric oxide synthesis in rat peritoneal macrophages is induced by IgE/DNP complexes and cyclic AMP analogues Evidence in favor of a common signaling mechanism . J Immunol. 154:1995;6475-6483.
52. Mullet D., Fertel R.H., Kniss D., Cox G.W. An increase in intracellular cAMP modulates nitric oxide production in IFN-γ treated macrophages. J Immunol. 158:1997;897-904.
53. Coffey R.G., Yamamoto Y., Snella E., Pross S. Tetrahydrocannabinol inhibition of macrophage nitric oxide production. Biochem Pharmacol. 52:1996;743-751.
54. Xie H., Rothstein T.L. Protein kinase C mediates activation of nuclear cAMP response element-binding protein (CREB) in B lymphocytes stimulated through surface Ig. J Immunol. 154:1995;1717-1723.
55. Wilson B.E., Mochon E., Boxer L.M. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol. 16:1996;5546-5556.
56. Grieco D., Porcellini A., Avvedimento E.V., Gottesman M.E. Requirement for cAMP-PKA pathway activation by M phase-promoting factor in the transition from mitosis to interphase. Science. 271:1996;1718-1722.